New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
07:07 EDTGALEGalena receives U.S. patent for NeuVax
Galena Biopharma announced the notice of allowance of a U.S. Patent for NeuVax covering the use of NeuVax alone or in combination to prevent recurrence of any HER2/neu expressing tumor having a fluorescence in situ hybridization, or FISH, rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2028, not including any patent term extensions. FISH is a diagnostic test used to identify patients with high levels of HER2 gene expression, or FISH greater than 2.0. These patients are eligible for existing approved HER2-directed treatments. Currently there are no approved HER2-directed therapies for patients who express lower levels of HER2, or less than 2.0 by the FISH testing scale. The patent will cover the use of NeuVax in patients with a FISH of less then about 2.0, as a stand-alone therapy or in combination with an adjuvant and/or other agents. Importantly, this NeuVax patent provides Galena with coverage for any tumor expressing low-to-intermediate levels of HER2.
News For GALE From The Last 14 Days
Check below for free stories on GALE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Subscribe for More Information
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
07:21 EDTGALEGalena enters into licensing agreement with MonoSol Rx
MonoSol Rx announced that it has licensed Zuplenz to Galena Biopharma. Zuplenz is an oral soluble film, or OSF, for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm technology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use